Next Article in Journal
Task-Irrelevant Features in Visual Working Memory Influence Covert Attention: Evidence from a Partial Report Task
Previous Article in Journal
Inhibitory and Facilitatory Cueing Effects: Competition between Exogenous and Endogenous Mechanisms
Open AccessArticle

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients

1
Novartis Pharma AG, 4002 Basel, Switzerland
2
Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia
3
IQVIA Commercial GmbH & Co. OHG, 60549 Frankfurt, Germany
*
Author to whom correspondence should be addressed.
Vision 2019, 3(3), 41; https://doi.org/10.3390/vision3030041
Received: 4 July 2019 / Revised: 7 August 2019 / Accepted: 21 August 2019 / Published: 26 August 2019
Treat and extend (T&E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented. This retrospective, non-comparative, non-randomised study of eyes with nAMD classified treatment interval sequences in a T&E cohort in Australia using Electronic Medical Records (EMR) data. We analysed data from 632 treatment-naïve eyes from 555 patients injected with ranibizumab, aflibercept or unlicensed bevacizumab between January 2012 and June 2016 (mean baseline age 78.0). Eyes were categorised into non-overlapping clusters of interval sequences based on the first 12 months of follow-up. We identified 523 different treatment interval sequences. The largest cluster of 197 (31.5%) eyes attained an 8-week treatment interval before dropping to a shorter frequency, followed by 168 (26.8%) eyes that did not reach or attained a single 8-week interval at the end of the study period. A total of 65 (10.4%) and 83 (13.3%) eyes reached and sustained (≥2 consecutive injection intervals of the same length) an 8 and 12 weekly interval, respectively. This study demonstrates highly individualised treatment patterns in the first year of anti-VEGF therapy in Australia using T&E regimens, with the majority of patients requiring more frequent injections than once every 8 weeks. View Full-Text
Keywords: nAMD; anti-VEGF; unlicensed bevacizumab; aflibercept; ranibizumab; age-related macular degeneration; treat and extend nAMD; anti-VEGF; unlicensed bevacizumab; aflibercept; ranibizumab; age-related macular degeneration; treat and extend
Show Figures

Figure 1

MDPI and ACS Style

Skelly, A.; Bezlyak, V.; Liew, G.; Kap, E.; Sagkriotis, A. Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision 2019, 3, 41.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop